Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 4Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumor 1Skin Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Inflammatory Breast Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Craniopharyngioma 1Cholangiocarcinoma 1Carcinosarcoma 1Brain Neoplasms 1

Interventions

trametinib 3pembrolizumab 2lenvatinib 2dabrafenib 2Paclitaxel 2Nivolumab 2selpercatinib 1fludarabine 1cobimetinib 1atezolizumab 1aldesleukin 1Vemurafenib 1Taxes 1Radiotherapy, Intensity-Modulated 1Ipilimumab 1Immunoglobulin G 1Disulfides 1Cyclophosphamide 1CTLA-4 Antigen 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Thyroid Carcinoma, Anaplastic × cobimetinib × Clear all
NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
50 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡